PTC Therapeutics reported $83.5M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Cytokinetics USD -190.07M 8.69M Sep/2026
Daiichi Sankyo JPY 82.9B 14.26B Sep/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD -10.5B 12.52B Jun/2026
Incyte USD -784.8M 1.37B Sep/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Novartis USD 1.2B 2.06B Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
PTC Therapeutics USD 83.5M 86.3M Jun/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
TG Therapeutics USD 55.46M 47.68M Sep/2026
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026
Xencor USD -21.73M 107.19M Jun/2026